psalexa
logo

Mantle Cell Lymphoma Therapeutics Pipeline Analysis

Mantle Cell Lymphoma Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11237
Available Format:

Mantle cell lymphoma is a kind of disease that affects the lymphatic system (which is a part of immune system). Mantle cell lymphoma is life-threatening, slow-growing cancers which involves accumulation of cancerous B-cells at mantle zone in the lymph node. Mantle cell lymphoma can be symptomatized by night sweats, fever, weight loss and fatigue. Intestinal obstruction, multiple intestinal polyps, high blood count, and intussusception are observed in patients with mantle cell carcinoma. Somatic DNA damage is observed as the major cause of mantle cell lymphoma. The disease can be diagnosed by lymph node biopsy, bone marrow biopsy, and flow cytometry. Immunohistochemistry, cytogenetic analysis, immunophenotyping, and fluorescence in situ hybridization (FISH) are the tests to study the cancer cells. Millennium Pharmaceuticals, Inc. is in the process of developing ixazomib as a proteasome inhibitor for the treatment of mantle cell lymphoma. Merck Sharp & Dohme Corp. is in the process of developing ibrutinib as a bruton's tyrosine kinase inhibitor for the treatment of mantle cell lymphoma. Some of the companies having the pipeline of mantle cell lymphoma include Millennium Pharmaceuticals, Inc., Kite Pharma, Inc., Merck Sharp & Dohme Corp., and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry